AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30139537 — intervention group
Group type: COMPARATOR
Intervention: Patient selection by the number of prescribed drugs
Number of subjects: 78
Study 30139537 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived personal advantage of MR
Number of subjects: 78
Study 30139537 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of MR
Number of subjects: 78
Study 27182024 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed feedback practice using smartphone videos
Number of subjects: 58
Study 24325891 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving Behavior Survey (DBS) scores
Number of subjects: 40
Study 20830241 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG cream (2.5% w/w) applied twice daily for six weeks
Number of subjects: 4
Study 17499035 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavity triamcinolone 80 mg (Group A, n=29)
Number of subjects: 49
Study 17499035 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group B, n=23)
Number of subjects: 49
Study 17499035 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavity triamcinolone 80 mg (Group A)
Number of subjects: 49
Study 17499035 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group B)
Number of subjects: 49
Study 16639473 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric endurance of the vastus lateralis muscle in CHF patients
Number of subjects: 25
Study 16639473 — intervention group
Group type: COMPARATOR
Intervention: Isometric endurance of the vastus lateralis muscle in healthy subjects (HS)
Number of subjects: 25
Study 16639473 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate synthase (CS) activity in CHF patients
Number of subjects: 25
Study 16639473 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexokinase (HK) activity in CHF patients
Number of subjects: 25
Study 16639473 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphofructokinase (PFK) activity in CHF patients
Number of subjects: 25
Study 16639473 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of T(F) with CS activity
Number of subjects: 25
Study 16639473 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of T(F) with HADH activity
Number of subjects: 25
Study 16639473 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of T(F) with PFK activity
Number of subjects: 25
Study 16639473 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of T(F) with HK activity
Number of subjects: 25
Study 16639473 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of T(F) with PFK/CS ratio
Number of subjects: 25
Study 16639473 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of T(F) with HADH activity in CHF group
Number of subjects: 25
Study 16639473 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of T(F) with PFK activity in CHF group
Number of subjects: 25
Study 12798615 — intervention group
Group type: EXPERIMENTAL
Intervention: vax‐TyVi (Salmonella Typhi Vi polysaccharide vaccine)
Number of subjects: 0
Study 12798615 — intervention group
Group type: COMPARATOR
Intervention: TYPHIM Vi (control vaccine)
Number of subjects: 0
Study 12798615 — intervention group
Group type: COMPARATOR
Intervention: tetanus toxoid vaccine (control)
Number of subjects: 0
Study 11028464 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical valve
Number of subjects: 575
Study 11028464 — intervention group
Group type: COMPARATOR
Intervention: Bioprosthetic valve
Number of subjects: 575
Study 11028464 — intervention group
Group type: COMPARATOR
Intervention: Bioprosthetic AVR
Number of subjects: 575
Study 11028464 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 575
Study 8606270 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose dobutamine (5 to 10 microg/kg body weight per min)
Number of subjects: 49
Study 8606270 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose dobutamine (20 to 40 microg/kg body weight per min)
Number of subjects: 49
Study 8179456 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (14 mg/d, increased to 21 mg/d if smoking more than seven cigarettes after 1 week)
Number of subjects: 156
Study 8179456 — intervention group
Group type: COMPARATOR
Intervention: Transdermal placebo
Number of subjects: 156
Study 8179456 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 156
Study 8179456 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine and placebo
Number of subjects: 156
Study 2851195 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard heparin, 5,000 I.U.
Number of subjects: 6
Study 2851195 — intervention group
Group type: EXPERIMENTAL
Intervention: Kabi 2165, 10,000 anti‐Xa U
Number of subjects: 6
Study 2851195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2851195 — intervention group
Group type: COMPARATOR
Intervention: Kabi 2165, 5,000 anti‐Xa U
Number of subjects: 6
Study 30964340 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark play
Number of subjects: 157
Study 30964340 — intervention group
Group type: COMPARATOR
Intervention: Normal play
Number of subjects: 157
Study 28548024 — intervention group
Group type: EXPERIMENTAL
Intervention: Omarigliptin 25 mg once-weekly
Number of subjects: 751
Study 28548024 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride up to 6 mg once daily
Number of subjects: 751
Study 27345747 — intervention group
Group type: EXPERIMENTAL
Intervention: SMT+HEA
Number of subjects: 241
Study 27345747 — intervention group
Group type: COMPARATOR
Intervention: HEA
Number of subjects: 241
Study 27345747 — intervention group
Group type: COMPARATOR
Intervention: SRE+HEA
Number of subjects: 241
Study 23340506 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0
Study 23340506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21103657 — intervention group
Group type: EXPERIMENTAL
Intervention: Solulin (0.6-30 mg single doses)
Number of subjects: 42
Study 21103657 — intervention group
Group type: EXPERIMENTAL
Intervention: Solulin (1 and 10 mg multiple doses)
Number of subjects: 42
Study 21103657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 19470722 — intervention group
Group type: EXPERIMENTAL
Intervention: ECGs with erroneous computer interpretation (citing acute ischemia)
Number of subjects: 105
Study 19470722 — intervention group
Group type: COMPARATOR
Intervention: ECGs without erroneous computer interpretation
Number of subjects: 105
Study 19470722 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents who read the ECG as diagnostic of ischemia with erroneous computer interpretation
Number of subjects: 105
Study 19470722 — intervention group
Group type: COMPARATOR
Intervention: Residents who read the ECG as diagnostic of ischemia without erroneous computer interpretation
Number of subjects: 105
Study 16881775 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal cognitive-behavioral treatment package
Number of subjects: 64
Study 16881775 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 64
Study 15621114 — intervention group
Group type: EXPERIMENTAL
Intervention: AUC(0-4) > or = 4000 ng . h/mL or C(2) > or = 1450 ng/mL (no induction therapy)
Number of subjects: 58
Study 15621114 — intervention group
Group type: EXPERIMENTAL
Intervention: C(2) of 1043 +/- 151 ng/mL or AUC(0-4) of 3146 +/- 262 ng . h/mL (with induction therapy)
Number of subjects: 58
Study 15621114 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with basiliximab or thymoglobulin
Number of subjects: 58
Study 11212082 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 1014
Study 11212082 — intervention group
Group type: COMPARATOR
Intervention: Other GnRH agonists
Number of subjects: 1014
Study 9289451 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic fluid from women with pregnancy complicated by hypertension
Number of subjects: 62
Study 9289451 — intervention group
Group type: COMPARATOR
Intervention: Amniotic fluid from healthy pregnant women (control group)
Number of subjects: 62
Study 9289451 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal kidney maturation in pregnancy complicated by hypertension
Number of subjects: 62
Study 2055157 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine maleate
Number of subjects: 0
Study 2055157 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0
Study 2055157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6496647 — intervention group
Group type: EXPERIMENTAL
Intervention: Thick hydrogel contact lens wear on one eye
Number of subjects: 8
Study 6496647 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral eye without lens)
Number of subjects: 8
Study 30612559 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 2107
Study 30612559 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 2107
Study 30612559 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin
Number of subjects: 2107
Study 30612559 — intervention group
Group type: COMPARATOR
Intervention: Macrolides (azithromycin, clarithromycin, erythromycin)
Number of subjects: 2107
Study 30612559 — intervention group
Group type: COMPARATOR
Intervention: Fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin)
Number of subjects: 2107
Study 30127595 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 32 mg alone
Number of subjects: 20
Study 30127595 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg alone
Number of subjects: 20
Study 30127595 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 32 mg and Amlodipine 10 mg co-administration
Number of subjects: 20
Study 30127595 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study 25308749 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower medical mistrust
Number of subjects: 671
Study 25308749 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater perceived self-efficacy
Number of subjects: 671
Study 25308749 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical mistrust
Number of subjects: 671
Study 23690319 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice facilitation activities
Number of subjects: 19
Study 23690319 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-visit practice facilitation protocol
Number of subjects: 19
Study 20832121 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep anterior lamellar keratoplasty (DALK)
Number of subjects: 56
Study 20832121 — intervention group
Group type: COMPARATOR
Intervention: Penetrating keratoplasty (PK)
Number of subjects: 56
Study 18369721 — intervention group
Group type: EXPERIMENTAL
Intervention: Two types of sex (vaginal plus oral or anal)
Number of subjects: 711
Study 18369721 — intervention group
Group type: EXPERIMENTAL
Intervention: Three types of sex (vaginal, oral, and anal)
Number of subjects: 711
Study 18369721 — intervention group
Group type: COMPARATOR
Intervention: Vaginal sex only
Number of subjects: 711
Study 18369721 — intervention group
Group type: EXPERIMENTAL
Intervention: Having >/= 4 lifetime sex partners
Number of subjects: 711
Study 18369721 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a casual sex partner and having multiple sex partners in the last 60 days
Number of subjects: 711
Study 17803435 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.2%
Number of subjects: 126
Study 17803435 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 126
Study 15166554 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil combination
Number of subjects: 24
Study 11271695 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 409
Study 11271695 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face interview
Number of subjects: 409
Study 11271695 — intervention group
Group type: COMPARATOR
Intervention: Telephone interviews in telephone households
Number of subjects: 409
Study 11271695 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face interviews in non-telephone households
Number of subjects: 409
Study 9603075 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine administered at 1 day post-splenectomy
Number of subjects: 59
Study 9603075 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine administered at 7 days post-splenectomy
Number of subjects: 59
Study 9603075 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine administered at 14 days post-splenectomy
Number of subjects: 59
Study 9603075 — intervention group
Group type: COMPARATOR
Intervention: Normal adult control group (n = 12)
Number of subjects: 59
Study 8554468 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroneal stimulator (PS) during treatment period
Number of subjects: 17
Study 8554468 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control period)
Number of subjects: 17
Study 2675496 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (Mg 5‐longoral, Artesan GmbH)
Number of subjects: 50
Study 2675496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 819446 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium etidronate
Number of subjects: 4
Study 819446 — intervention group
Group type: COMPARATOR
Intervention: No drug (control)
Number of subjects: 4
Study 30982447 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (2.0 × 10^8 CFU probiotics and 394 mg fructooligosaccharide)
Number of subjects: 57
Study 30982447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 30982447 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 57
Study 28664036 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual brain biopsy using imaging metrics (white matter diffusivity indices, grey matter T1-signal intensity values, basal ganglia volumes)
Number of subjects: 150
Study 28664036 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 150
Study 25361829 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretransplant diabetes
Number of subjects: 628
Study 25361829 — intervention group
Group type: EXPERIMENTAL
Intervention: NODAT (t)
Number of subjects: 628
Study 25361829 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised trials (1 to 4)
Number of subjects: 628
Study 23249928 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Number of subjects: 61
Study 23249928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 21777032 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with propofol (group T)
Number of subjects: 45
Study 21777032 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anesthesia (group R)
Number of subjects: 45
Study 21777032 — intervention group
Group type: COMPARATOR
Intervention: General inhalational anesthesia with sevoflurane (group S)
Number of subjects: 45
Study 19780729 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI-NO training
Number of subjects: 276
Study 16144748 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg buprenorphine tablets (two 8 mg tablets)
Number of subjects: 24
Study 16144748 — intervention group
Group type: COMPARATOR
Intervention: 8 mg buprenorphine solution (1 ml at 8 mg/ml)
Number of subjects: 24
Study 15361758 — intervention group
Group type: EXPERIMENTAL
Intervention: Light exercise (LITE) at 40% of maximal oxygen consumption
Number of subjects: 49
Study 15361758 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise (MOD) at 60% of maximal oxygen consumption
Number of subjects: 49
Study 15361758 — intervention group
Group type: COMPARATOR
Intervention: Control session (no exercise)
Number of subjects: 49
Study 11144006 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (20 mg twice daily for 6 months)
Number of subjects: 40
Study 11144006 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cisapride)
Number of subjects: 40
Study 9291422 — intervention group
Group type: EXPERIMENTAL
Intervention: cetirizine 10 mg
Number of subjects: 111
Study 9291422 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine 60 mg
Number of subjects: 111
Study 9291422 — intervention group
Group type: EXPERIMENTAL
Intervention: loratadine 10 mg
Number of subjects: 111
Study 9291422 — intervention group
Group type: EXPERIMENTAL
Intervention: astemizole 10 mg
Number of subjects: 111
Study 9291422 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 111
Study 8100688 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 micrograms.kg-1
Number of subjects: 35
Study 8100688 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine 0.25, 0.5, 0.75, 1.0 and 1.5 micrograms.kg-1
Number of subjects: 35
Study 2906345 — intervention group
Group type: EXPERIMENTAL
Intervention: GTD-containing pill
Number of subjects: 176
Study 2906345 — intervention group
Group type: COMPARATOR
Intervention: LNG-containing pill
Number of subjects: 176
Study 28832435 — intervention group
Group type: EXPERIMENTAL
Intervention: Reengagement Outreach (RO) group
Number of subjects: 3020
Study 28832435 — intervention group
Group type: COMPARATOR
Intervention: Comparison (no outreach) group
Number of subjects: 3020
Study 28095580 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-hydroquinone lightening product (JM)
Number of subjects: 0
Study 28095580 — intervention group
Group type: COMPARATOR
Intervention: 4% Hydroquinone lightening solution (OB)
Number of subjects: 0
Study 25137843 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiawei Shentong Zhuyu Decoction (JSZD), one dose per day, taken in two portions (morning and evening) for 30 days
Number of subjects: 100
Study 25137843 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib Capsule (200 mg once per day) and Mecobalamin Tablet (0.5 mg three times per day, only Mecobalamin from day 11) for 30 days
Number of subjects: 100
Study 22265118 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 44
Study 22265118 — intervention group
Group type: COMPARATOR
Intervention: Nutrition counseling
Number of subjects: 44
Study 20384423 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (1.14 mg nicotine, 15.9 mg tar)
Number of subjects: 127
Study 20384423 — intervention group
Group type: COMPARATOR
Intervention: Denicotinized cigarettes (.06 mg nicotine, 17.9 mg tar)
Number of subjects: 127
Study 20384423 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (men: 0.8 g/kg; women: 0.7 g/kg)
Number of subjects: 127
Study 20384423 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 127
Study 18520312 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic care intervention for depression treatment
Number of subjects: 395
Study 18520312 — intervention group
Group type: EXPERIMENTAL
Intervention: Summary measure of beliefs
Number of subjects: 395
Study 18520312 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 395
Study 15992557 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamilton Rating Scale for Depression (HRSD(24)) early insomnia items
Number of subjects: 397
Study 15992557 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamilton Rating Scale for Depression (HRSD(24)) middle insomnia items
Number of subjects: 397
Study 15992557 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamilton Rating Scale for Depression (HRSD(24)) late insomnia items
Number of subjects: 397
Study 15992557 — intervention group
Group type: EXPERIMENTAL
Intervention: Inventory of Depression Symptoms - Self Report (IDS-SR(30)) early insomnia items
Number of subjects: 397
Study 15992557 — intervention group
Group type: EXPERIMENTAL
Intervention: Inventory of Depression Symptoms - Self Report (IDS-SR(30)) middle insomnia items
Number of subjects: 397
Study 15992557 — intervention group
Group type: EXPERIMENTAL
Intervention: Inventory of Depression Symptoms - Self Report (IDS-SR(30)) late insomnia items
Number of subjects: 397
Study 15992557 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily sleep efficiency
Number of subjects: 397
Study 15992557 — intervention group
Group type: EXPERIMENTAL
Intervention: Unit increments in HRSD(24) scores for early, middle, and late insomnia
Number of subjects: 397
Study 15992557 — intervention group
Group type: EXPERIMENTAL
Intervention: Unit increments in IDS-SR(30) scores for early insomnia
Number of subjects: 397
Study 12495099 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-gloving
Number of subjects: 170
Study 12495099 — intervention group
Group type: COMPARATOR
Intervention: Single gloves
Number of subjects: 170
Study 10525141 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/day of alpha-tocopherol
Number of subjects: 1484
Study 10525141 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day of beta-carotene
Number of subjects: 1484
Study 10525141 — intervention group
Group type: EXPERIMENTAL
Intervention: Both alpha-tocopherol and beta-carotene
Number of subjects: 1484
Study 10525141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1484
Study 7723385 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose monthly maintenance therapy
Number of subjects: 522
Study 7723385 — intervention group
Group type: EXPERIMENTAL
Intervention: Late intensification plus monthly maintenance
Number of subjects: 522
Study 7723385 — intervention group
Group type: COMPARATOR
Intervention: Late intensification alone
Number of subjects: 522
Study 7723385 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic marrow transplantation in first CR
Number of subjects: 522
Study 7723385 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with donors not transplanted in first CR
Number of subjects: 522
Study 7723385 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients less than age 50 without donors
Number of subjects: 522
Study 7723385 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of M3 AML
Number of subjects: 522
Study 1904551 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (20 mg per milliliter) administered continuously in aerosolized form
Number of subjects: 28
Study 1904551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 7392895 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycling
Number of subjects: 38
Study 7392895 — intervention group
Group type: EXPERIMENTAL
Intervention: Tennis
Number of subjects: 38
Study 7392895 — intervention group
Group type: EXPERIMENTAL
Intervention: Jogging
Number of subjects: 38